Effectiveness and Implementation of 'Supportive and Palliative Care Review Kit in Locations Everywhere'

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-120
SponsorNational Cancer Centre, Singapore

About this trial

Advanced cancer patients often experience significant physical and emotional symptoms, which can lead to frequent hospital visits and reduced quality of life. Although palliative care can help manage these symptoms and improve well-being, it is often introduced too late.

A proactive symptom monitoring model, SPARKLE-2 aims to identify patients who need palliative care earlier by regularly checking their symptoms using a simple questionnaire. Patients with concerned symptoms will receive timely support from the palliative care team, with the goal of improving their quality of life, reducing unnecessary hospital admissions, and helping more patients receive care in the community rather than in hospital. In the earlier SPARKLE-1 study, it showed the improvement of patients' physical wellbeing. SPARKLE-2 seeks to test the effectiveness among advanced cancer patients with unplanned hospital visits while simultaneously collecting data on real-world implementation.

Eligibility criteria

Qualifiers

21 years old or older

Diagnosed of advanced cancer diagnosis, defined as metastatic or recurrent/ progressive Stage III/IV solid tumour

Has an unplanned hospital admission and expected to be discharged home

Able to speak English or Mandarin Chinese or Malay

Disqualifiers

Assessed by the treating physician as unable to complete study procedures

Unable to complete patient-reported outcome measures

Healthcare professionals that are not providing care for cancer patients.

Unable to complete interviews

Trial design

Treatments tested in this trial

  • SPARKLE-2

Treatment groups

300 Participants
are divided into 2 treatment groups